2328 completed, 791 unknown, 685 recruiting, 491 terminated. 1453 Phase 2, 1230 Phase 1, 1038 Not applicable, 416 Phase 3, 188 Phase 4.
Follow Ovarian Diseases: new trials by email Literature Review of Ovarian Diseases trials Research Report on Ovarian Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer | Not applicable | Not yet recruiting | Oncare Madrid | 32 | 2028-05-01 | 2026-10-08 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Not yet recruiting | ShangHai Ji Ai Genetics & IVF Institute | 204 | 2027-06-01 | 2026-11-09 |
| PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing | Not applicable | Not yet recruiting | Rachel Miller | 200 | 2027-04-01 | 2026-09-10 |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2027-03-31 | 2026-11-13 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial Time-restricted eating - Polycystic Ovary Syndrome | Not applicable | Not yet recruiting | Joanna Bajerska | 84 | 2027-01-09 | 2026-10-16 |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 534 | 2026-12-31 | 2026-11-12 |
| The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome Synbiotic Supplement, Placebo - PCOS (Polycystic Ovary Syndrome) | Not applicable | Recruiting | Atlas University | 32 | 2026-12-20 | 2026-10-28 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot Ketogenic diet, Exogenous Ketone Supplement - PCOS (Polycystic Ovary Syndrome) | Not applicable | Recruiting | Ohio State University | 40 | 2026-12-01 | 2026-05-08 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-12-01 | 2026-11-09 |
| A Study of LY4336619 in Adult Participants With Advanced Solid Tumors LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 | Not yet recruiting | Eli Lilly and Company | 370 | 2026-12-01 | 2026-11-10 |
| Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian) Exercise, Usual Care - High Grade Serous Ovarian, Ovarian Adenocarcinoma | Not applicable | Not yet recruiting | University of Pittsburgh | 20 | 2026-12-01 | 2026-11-12 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-11-15 | 2026-11-09 |
| Effects of Pilates Exercises on Doppler Parameters in Obese Females With Polycystic Ovarian Syndrome Mediterranean diet, Pilates exercise - Polycystic Ovary Syndrome | Not applicable | Not yet recruiting | Cairo University | 40 | 2026-11-15 | 2026-11-13 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
Showing 20 of 4983. Sign in to see all of them.
Ovarian Neoplasms (3271) · Polycystic Ovary Syndrome (956) · Carcinoma, Ovarian Epithelial (787) · Fallopian Tube Neoplasms (784) · Breast Neoplasms (687) · Endometrial Neoplasms (454) · Neoplasms (370) · Uterine Cervical Neoplasms (361) · Carcinoma, Non-Small-Cell Lung (339) · Pancreatic Neoplasms (325) · Colorectal Neoplasms (320) · Stomach Neoplasms (268) · Prostatic Neoplasms (256) · Lung Neoplasms (254) · Melanoma (212)
Female Urogenital Diseases (4982) · Female Urogenital Diseases and Pregnancy Complications (4982) · Genital Diseases (4982) · Urogenital Diseases (4982) · Adnexal Diseases (4973) · Genital Diseases, Female (4968) · Gonadal Disorders (4968) · Endocrine System Diseases (4959) · Neoplasms (4339) · Neoplasms by Site (3690) · Urogenital Neoplasms (3680) · Endocrine Gland Neoplasms (3673) · Genital Neoplasms, Female (3665) · Neoplasms by Histologic Type (1448)
Paclitaxel (380) · Carboplatin (372) · Bevacizumab (209) · Metformin (169) · liposomal doxorubicin (123) · Gemcitabine (121) · pembrolizumab (119) · Cisplatin (108) · Cyclophosphamide (104) · Topotecan (104) · olaparib (101) · niraparib (74) · Taxes (71) · Letrozole (67) · Clomiphene (63)
National Cancer Institute (NCI) (190) · Memorial Sloan Kettering Cancer Center (84) · M.D. Anderson Cancer Center (83) · Gynecologic Oncology Group (77) · AstraZeneca (64) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (45) · Cairo University (38) · Dana-Farber Cancer Institute (37) · Eli Lilly and Company (32) · Mayo Clinic (31) · University of Virginia (31) · City of Hope Medical Center (26) · Masonic Cancer Center, University of Minnesota (26) · Pfizer (26) · University Health Network, Toronto (26)
United States (2245) · China (562) · France (356) · Italy (338) · United Kingdom (327) · Canada (322) · Spain (310) · Germany (219) · Belgium (215) · Australia (194) · South Korea (192) · Egypt (151) · Netherlands (149) · Turkey (Türkiye) (134) · Denmark (126)
Lei Li, M.D. (14) · Stefano Palomba, MD (14) · Paul Sabbatini, MD (13) · Francesco Orio, MD (10)
PMID 37185961, PMID 37407274, PMID 35170751, PMID 27008889, PMID 37462232, PMID 39695768, PMID 19238149, PMID 30633128, PMID 20818904, PMID 23922302, PMID 26961146, PMID 29342393, PMID 29486615, PMID 35537408, PMID 36512649, PMID 39019698, PMID 41868592, PMID 42693220, PMID 14688154, PMID 16394300, PMID 18158291, PMID 20424285, PMID 21324454, PMID 21941283, PMID 26707054, PMID 30796792, PMID 31547562, PMID 32195207, PMID 33347618, PMID 33538338, PMID 34904813, PMID 35262624, PMID 35397664, PMID 40132910, PMID 40785326, PMID 41044356, PMID 42014131, PMID 12826431, PMID 16882940, PMID 16966687, PMID 17000396, PMID 17949799, PMID 18480812, PMID 19282241, PMID 19427025, PMID 19556464, PMID 19949018, PMID 20351977, PMID 20858697, PMID 21123449
U10CA027469 (59), U10CA180868 (45), 2023 (35), 2018 (25), 2025 (23), 2017 (18), P30CA033572 (18), 2016 (17), 2008 (16), 2015 (16), 2009 (15), P30CA015083 (14), U10CA101165 (11), 2019 (10), P30CA016672 (9)